Streamline lupus patient care
with GSK GmbH & Co. KG

Disruptive solutions for early disease identification and lack of quality of care regarding disease control adjusted treatment of systemic lupus erythematosus [1]

1 Chavatza K, Kostopoulou M, Nikolopoulos D, et al. Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Ann Rheum Dis. 2021 Sep;80(9):1175-1182. doi: 10.1136/annrheumdis-2021-220438. Epub 2021 Jun 23. PMID: 34162597.

2 Lupus Foundation of America Introduction to Lupus. Statistics on lupus. (Letzter Zugriff 01.09.2017)

3 Brinks et al, Lupus 2014 Nov; 23 (13); 1407-11

4 Urowitz MB, Gladman DD, Tom BDM et al. Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus. J Rheumatol 2008;35:2152-8

5 Chehab G, Fischer-Betz R, Schneider M Entwicklung von Mortalität und Morbidität beim systemischen Lupus erythematodes. Z Rheumatol 2011; 70: 480-485

6 U.S. Department of Health and Human Services. Handout on Health: Systemic Lupus Erythematosus. NIH Publication No. 03-4178. August 2003

Challenge owner

GSK GmbH & Co. KG

Disease area

Systemic Lupus Erythematosus

Registration deadline

16 April 2023



What we are looking for:

Systemic autoimmune diseases often cause multi organ involvement and highly variable unspecific symptoms, which leads to tedious patient pathways, often lacking effective interdisciplinary management approaches. This results in severely impaired quality of life, early organ damage and worse prognosis. SLE is a rare disease, and most physicians are not sufficiently experienced in its management, which has essentially changed over the last decade. The knowledge gap and time pressure of physicians and the high need for answers and information from patients result in a huge burden for the physician-patient relationship und a huge gap in quality of care.

GSK GmbH & Co. KG is calling for disruptive, innovative solutions that can be applied to facilitate and improve disease state adjusted therapy (incl. measurement of disease activity with a tool such as the SLEDAI) early disease identification and hence treatment, for patients suffering from SLE.

Solutions could address but are not limited to:

  • Diagnostic devices and/or tools to support HCPs and patients in earlier diagnosis.
  • Decentralized metaverse or digital platforms to facilitate diagnosis, timely treatment escalation and others.
  • Innovative tools that enable disease monitoring and support disease management to fasten patient pathways and timely treatment escalation

Easy integration in daily clinical workflow is an essential prerequisite. The solution needs to be validated with the end users (HCP), needs to be based on data supporting theevidence and showing its impact and has all required approvals.

Incorporated companies with a product or technology that addresses the challenges released. At least, a prototype of the solution should exist. There are no further specific requirements in terms of Technology Readiness Level (TLR), sales, minimum investment attracted, or country of registration.

European and non-European SMEs are invited to apply.  

Click on „Apply now“ and follow the instructions to submit an application. You will answer different questions about your company and the product you present as a possible solution to the challenge. 

The main selection criteria is product-challenge fit. Applications are sent to the relevant teams in each challenge-owner, who decide which companies are selected. To increase the chances of a successful application, make sure you carefully read the information we have published about each challenge and show in your application how your product could be a perfect match. The questions in the application will guide you!

Yes, of course! However, you will need to submit one individual application per challenge and customize it according to the challenge.

Yes, the main requirement is that your solution addresses the challenge. In case you are selected, during the meetings with the challenge owners, you can clarify the needs of both parties and decide on possible changes/modifications/extra features, etc. 

We encourage you to apply even if your solution only fulfills some of the requirements of the „ideal solution“ described above. Both off-the-shelf and customizable options are relevant!

Mostly online, with the possibility to organize meetings in person in the Meet&Visit module. 

None, it is completely free of charge. No fee, no equity taken. You only need to bring professionalism and commitment to make the best out of this opportunity. 

Neither party is obliged to enter into a partnership. We will create the optimal environment for a collaboration to start, but whether this happens, and the conditions of the collaboration, will be exclusively decided by the parties involved. 

However, we guarantee 100% of the selected companies will be connected to the relevant teams within the challenge-owner, will have 1-on-1 partnership exploration meetings, and will receive support to prepare for that occasion in the best possible way. 

We constantly release different challenges in collaboration with industry leaders and healthcare providers. Join our start-ups database and you will be immediately notified when new challenges are out! 

Scroll to Top